Myths and facts in the use of anti-inflammatory drugs (Q37476911)

20 August 2017

1 reference

title

Myths and facts in the use of anti-inflammatory drugs (English)

1 reference

20 August 2017

0 references

2

Angel Lanas

1 reference

20 August 2017

Richard H Hunt

1

1 reference

20 August 2017

Dirk O Stichtenoth

series ordinal

3

1 reference

20 August 2017

Carmelo Scarpignato

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

41

1 reference

20 August 2017

6

1 reference

20 August 2017

423-437

1 reference

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

20 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Aspirin: promise and resistance in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

High prevalence of NSAID enteropathy as shown by a simple faecal test

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Effect of ibuprofen on cardioprotective effect of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

21 January 2018

COX-2 and the kidneys

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Ibuprofen-associated renal impairment in a large general internal medicine practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Relationship between COX-2 specific inhibitors and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Parecoxib, valdecoxib, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Time-to-Event Analyses for Long-Term Treatments — The APPROVe Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Smoking, haemostatic factors, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Association between SSRIs and upper gastrointestinal bleeding. Coprescription of antiulcer drugs with SSRIs is fairly common

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Antidepressants and risk of upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890902887295

10.1080/07853890902887295

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference